Meiji Holdings Co (JP:2269) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Meiji Holdings Co. subsidiary Meiji Seika Pharma Co., Ltd. has obtained approval in Japan for a partial amendment to manufacture and market its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE®, tailored to the Omicron subvariant JN.1. The vaccine, which has demonstrated a strong immune response and good tolerability in clinical trials, is slated for distribution in the upcoming 2024/2025 season in a 16-dose vial format. This development is not expected to affect the company’s consolidated earnings forecast for the fiscal year ending March 2025.
For further insights into JP:2269 stock, check out TipRanks’ Stock Analysis page.